4Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug
Summary
View the full release here: https://www.businesswire.com/news/home/20250407335930/en/France 2030 is a highly selective and strategic initiative by the French government designed to fast-track the next generation of breakthrough innovations. "This additional funding will accelerate the 4P004 INFLAM MOTION Phase 2a clinical study, a GLP-1 analog designed to harness anti-inflammatory, analgesic, anti-catabolic, and anabolic effects across all joint tissues. France 2030 is defined by two overarching objectives, which will see 50% of expenses given over to the decarbonization of the economy, and 50% to emerging key players, those at the forefront of innovation, without neglecting the environment (in the sense of the Do No Significant Harm principle). France 2030 is being implemented collectively: designed and deployed in consultation with economic, academic, local and European key players to establish strategic guidelines and decisive action. For more information, please visit: https://www.bpifrance.com/ Follow us on Twitter: @Bpifrance - @BpifrancePresse and LinkedInThe only version of the 4Moving Biotech press release that is legally binding is the one in its original language.